BNT162b5 Bivalent
/ BioNTech
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
April 11, 2024
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2/3 | N=1454 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 24, 2023
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2/3 | N=1424 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting | N=700 ➔ 1424
Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 23, 2023
A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2/3 | N=700 | Recruiting | Sponsor: BioNTech SE | Phase classification: P2 ➔ P2/3
Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 07, 2023
A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2 | N=700 | Recruiting | Sponsor: BioNTech SE | Active, not recruiting ➔ Recruiting | N=1143 ➔ 700 | Trial completion date: Apr 2023 ➔ Jan 2024 | Trial primary completion date: Apr 2023 ➔ Jan 2024
Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 21, 2022
A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2 | N=1143 | Active, not recruiting | Sponsor: BioNTech SE | Phase classification: P2/3 ➔ P2
Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 07, 2022
Safety and Effects of an Investigational COVID-19 Vaccine as a Booster in Healthy People
(clinicaltrials.gov)
- P1 | N=180 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 14, 2022
A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2/3 | N=1143 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting | Phase classification: P2 ➔ P2/3
Enrollment closed • Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 03, 2022
A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2 | N=1100 | Recruiting | Sponsor: BioNTech SE | N=700 ➔ 1100
Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 15, 2022
Safety and Effects of an Investigational COVID-19 Vaccine as a Booster in Healthy People
(clinicaltrials.gov)
- P1 | N=180 | Not yet recruiting | Sponsor: BioNTech SE
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 14, 2022
A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals
(clinicaltrials.gov)
- P2 | N=700 | Recruiting | Sponsor: BioNTech SE | N=200 ➔ 700
Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 10, 2022
A Study to Learn About a New COVID-19 RNA Vaccine Candidate as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Adults
(clinicaltrials.gov)
- P2 | N=200 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 25, 2022
A Study to Learn About a New COVID-19 RNA Vaccine Candidate as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Adults
(clinicaltrials.gov)
- P2 | N=200 | Not yet recruiting | Sponsor: BioNTech SE
New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 12
Of
12
Go to page
1